• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vaccitech Plc ADR (NQ: VACC )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EST, Nov 6, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Vaccitech Plc ADR

    Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
    EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
    From Vaccitech plc
    Via GlobeNewswire
    Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
    From Vaccitech plc
    Via GlobeNewswire
    Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
    From Vaccitech plc
    Via GlobeNewswire
    Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
    From Vaccitech plc
    Via GlobeNewswire
    Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile
    From Vaccitech plc
    Via GlobeNewswire
    Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
    From Vaccitech plc
    Via GlobeNewswire
    Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments
    From Vaccitech plc
    Via GlobeNewswire
    Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions
    From Vaccitech plc
    Via GlobeNewswire
    Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer
    From Vaccitech plc
    Via GlobeNewswire
    Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
    From Vaccitech plc
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.